Managing Diabetes During Pregnancy: The Critical Role of Insulin Selection

Pregnancy complicated by diabetes demands exceptional glycemic discipline. Both maternal well-being and fetal development depend on maintaining glucose levels within a narrow physiological range. Insulin therapy remains the standard pharmacologic intervention, yet not all insulin formulations carry equal evidence for safety in pregnancy. Lyumjev (insulin lispro-aabc) entered the market as a rapid-acting insulin with accelerated absorption kinetics, offering advantages for postprandial glucose control in non-pregnant patients. However, its profile in pregnancy raises distinct questions. This review examines the pharmacologic properties of Lyumjev, evaluates the available safety data, and provides clinical guidance for practitioners managing pregnant women with diabetes.

Understanding Lyumjev: Mechanism and Pharmacokinetic Profile

Lyumjev, manufactured by Eli Lilly, contains insulin lispro as its active moiety — the same molecule found in Humalog. What distinguishes Lyumjev is its excipient formulation: the addition of citrate and treprostinil. These components enhance subcutaneous absorption by increasing local blood flow and accelerating the dissociation of insulin hexamers into monomers. The resulting time-action profile is faster than any other currently available rapid-acting insulin analog.

Following subcutaneous injection, Lyumjev reaches peak serum concentrations in approximately 13 minutes, with glucose-lowering effects evident within 15 minutes. Peak activity occurs between 30 and 90 minutes, and the total duration of action spans roughly 3 to 5 hours. For non-pregnant adults with type 1 or type 2 diabetes, this profile enables more precise meal-time dosing and improved postprandial glucose management.

Pregnancy introduces physiological changes that modify insulin pharmacokinetics. Increased subcutaneous adipose tissue, expanded plasma volume, and altered regional blood flow can influence both the rate and extent of insulin absorption. Whether Lyumjev accelerated profile translates to predictable benefits in pregnant women — or introduces new variables that complicate management — remains an area requiring careful scrutiny.

Physiologic Insulin Resistance in Pregnancy: Implications for Therapy

Pregnancy induces a progressive state of insulin resistance driven by placental hormones including human placental lactogen, cortisol, progesterone, and growth hormone variants. This resistance becomes clinically significant from the second trimester onward, often requiring substantial dose escalation. Women with preexisting type 1 or type 2 diabetes may need two to three times their pre-pregnancy insulin doses by the third trimester. Those with gestational diabetes who fail medical nutrition therapy similarly require escalating insulin doses to maintain glycemic targets.

Postprandial hyperglycemia correlates strongly with adverse maternal and fetal outcomes, including fetal hyperinsulinism, macrosomia, and neonatal hypoglycemia. The ideal rapid-acting insulin for pregnancy would produce a sharp, brief peak that closely matches the glucose excursion following a meal, then subside quickly to minimize late hypoglycemia risk. Lyumjev fast-on, fast-off profile theoretically aligns with this goal, but the narrow therapeutic window demands precise coordination between injection timing and carbohydrate intake. Pregnant women frequently experience unpredictable appetite, nausea, and delayed gastric emptying — factors that complicate the precise timing required for Lyumjev optimal use.

Placental Transfer and Fetal Exposure

A central safety concern with any medication in pregnancy is the potential for transplacental passage and fetal exposure. Insulin lispro, as a 51-amino-acid peptide, does not cross the placental barrier in clinically significant quantities due to its molecular size and polarity. Additionally, the placenta expresses insulin-degrading enzymes that actively metabolize insulin reaching the intervillous space. The excipients in Lyumjev — citrate and treprostinil — are present in picomolar concentrations that are orders of magnitude below therapeutic levels. Treprostinil, a prostacyclin analog with vasodilatory properties, is unlikely to achieve meaningful fetal concentrations following subcutaneous maternal administration. Nevertheless, no formal placental transfer studies specific to the Lyumjev formulation have been published. The absence of direct evidence does not confirm safety, but the available pharmacokinetic data suggest minimal fetal exposure is probable.

Regulatory Classification and Available Clinical Evidence

The United States Food and Drug Administration assigns Lyumjev to Pregnancy Category B. This classification indicates that animal reproduction studies have not demonstrated fetal risk, but adequate and well-controlled studies in pregnant women are lacking. For Lyumjev specifically, no animal reproduction studies using the novel formulation have been publicly reported. Studies with insulin lispro (Humalog) in rats and rabbits showed no evidence of teratogenicity, supporting the safety of the active ingredient itself.

As of 2025, no prospective clinical trials have evaluated Lyumjev in pregnant women with preexisting or gestational diabetes. Retrospective analyses, case series, and registry data are also absent from the published literature. Major professional organizations — including the American Diabetes Association and the American College of Obstetricians and Gynecologists — base their pregnancy management recommendations on insulin formulations with established safety records: human regular insulin, NPH, insulin lispro (Humalog), and insulin aspart (NovoLog). Lyumjev does not appear in current guidelines from these organizations. This absence reflects the lack of pregnancy-specific data rather than documented harm, but it carries clinical weight when selecting first-line therapy.

Risk Profile of Lyumjev in Pregnancy

Maternal Hypoglycemia

The most immediate clinical risk associated with Lyumjev in pregnancy is hypoglycemia. Pregnant women experience altered counter-regulatory hormone responses and are inherently more vulnerable to severe hypoglycemic events, particularly during the first trimester. Lyumjev rapid onset and abbreviated duration of action mean that any delay or reduction in carbohydrate intake following injection can produce a precipitous decline in blood glucose. Severe hypoglycemia in pregnancy carries risks of maternal seizures, loss of consciousness, and fetal distress, including stillbirth. Even mild or moderate hypoglycemic episodes, when recurrent, can impair maternal quality of life and reduce treatment adherence.

To reduce hypoglycemia risk in pregnant women using Lyumjev:

  • Rigorous meal timing with consistent carbohydrate content at each meal is essential
  • Blood glucose monitoring should occur before and after meals, and at bedtime
  • Continuous glucose monitoring with real-time low-glucose alerts is strongly recommended
  • Initial dosing should be conservative, with gradual upward titration based on postprandial glucose patterns
  • Patients must carry fast-acting glucose sources at all times

Fetal Safety Considerations

Both maternal hypoglycemia and hyperglycemia can adversely affect fetal development. Hyperglycemia during the first trimester — the period of organogenesis — increases the risk of congenital anomalies. Later in pregnancy, maternal hyperglycemia drives fetal hyperinsulinism, which promotes excessive fetal growth (macrosomia), neonatal hypoglycemia, and increased risk of metabolic complications in childhood. The theoretical risk from Lyumjev excipients is low given the subtherapeutic concentrations involved. However, the complete absence of long-term follow-up data on infants exposed to Lyumjev in utero means the safety picture remains incomplete. Until prospective cohort studies or registry data become available, this knowledge gap limits confidence in the formulation for routine use in pregnancy.

Absorption Variability in Pregnancy

Pregnancy alters subcutaneous tissue composition and blood flow. Injection site preferences also change as pregnancy progresses — many women avoid abdominal injections in later gestation due to skin stretching and discomfort, opting instead for thigh or arm sites. These sites may have different absorption characteristics when using a formulation designed to accelerate uptake through enhanced local blood flow. Lipohypertrophy from repeated insulin injections can further disrupt predictable absorption. The combination of altered physiology and injection site variability may reduce the reliability of Lyumjev pharmacokinetics in pregnant women compared to non-pregnant patients, potentially increasing glycemic variability and complicating dose adjustments.

Comparative Analysis: Lyumjev Versus Established Insulin Options

Human Regular Insulin (Humulin R, Novolin R)

Human regular insulin carries the longest record of safe use in pregnancy. Its onset of action is 30 to 60 minutes, peak activity occurs at 2 to 4 hours, and duration extends to 5 to 8 hours. While this slower profile can make postprandial glucose control more challenging — requiring patients to wait 30 minutes between injection and eating — it offers a wider margin of safety regarding hypoglycemia timing. Countless pregnancies have been managed with human regular insulin combined with NPH, with no evidence of teratogenicity. Many clinicians continue to use regular insulin as a component of basal-bolus regimens, particularly in settings where cost or formulary considerations limit access to analogs.

Insulin Aspart (NovoLog)

Insulin aspart holds FDA Pregnancy Category B designation and is explicitly recommended in professional guidelines for use in pregnancy. Its onset of 10 to 20 minutes, peak at 1 to 3 hours, and duration of 3 to 5 hours align favorably with postprandial glucose excursions. Large observational studies and one randomized controlled trial comparing insulin aspart to human regular insulin have demonstrated comparable maternal and fetal outcomes, with a lower incidence of hypoglycemia in the aspart group. The convenience of dosing immediately before meals and the extensive safety database make insulin aspart a common first-line rapid-acting analog in pregnant women with diabetes.

Insulin Lispro (Humalog)

Insulin lispro, the identical active ingredient found in Lyumjev, has been extensively studied in pregnancy. A meta-analysis encompassing over 1,000 pregnancies exposed to insulin lispro found no increased risk of major congenital anomalies, preterm delivery, or adverse perinatal outcomes when compared to human insulin. Humalog is well-tolerated, widely available, and routinely used throughout pregnancy. The critical distinction is that Humalog does not contain the absorption-enhancing excipients present in Lyumjev. Historical safety data on lispro cannot be fully extrapolated to the Lyumjev formulation because the excipients alter the pharmacokinetic profile in ways that may affect both efficacy and safety. For patients already established on Humalog who become pregnant, switching to Lyumjev offers no demonstrable advantage and introduces unnecessary uncertainty.

Insulin Glulisine (Apidra)

Insulin glulisine has limited published pregnancy data and does not appear in major guideline recommendations. Its use in pregnancy is uncommon. Lyumjev, despite representing a newer generation of rapid-acting technology, has even less pregnancy-specific evidence than glulisine.

Established Insulin Regimens for Gestational and Preexisting Diabetes

Clinicians managing pregnant women with diabetes can draw from several well-validated insulin regimens. Selection depends on patient preference, glycemic patterns, lifestyle factors, and formulary considerations.

Basal-Bolus with Human Insulins

  • NPH insulin administered once or twice daily provides basal coverage with extensive safety data
  • Human regular insulin dosed 30 to 60 minutes before meals covers prandial glucose excursions
  • A typical regimen combines NPH at breakfast and bedtime with regular insulin at each meal, allowing flexible adjustment based on pre-meal glucose levels and anticipated carbohydrate intake

Basal-Bolus with Rapid-Acting Analogs

  • Insulin aspart (NovoLog) or insulin lispro (Humalog) dosed immediately before meals
  • Basal options: NPH remains a first-line basal insulin in pregnancy. Insulin detemir (Levemir) carries Pregnancy Category B classification and has published safety data from randomized trials. Insulin glargine (Lantus) has less pregnancy-specific data but is used in clinical practice, particularly when transitioning from pre-pregnancy regimens
  • Many clinicians prefer analog-based regimens for their convenience and lower hypoglycemia risk compared to human regular insulin

Continuous Subcutaneous Insulin Infusion (Insulin Pump Therapy)

Insulin pumps offer precise, programmable basal rate delivery and on-demand bolus dosing. They are used during pregnancy, typically with insulin aspart or lispro. Some women find pumps provide greater flexibility for managing morning sickness, unpredictable appetite, and the evolving insulin resistance of later pregnancy. Lyumjev ultra-fast profile could theoretically benefit pump users by reducing the lag between bolus delivery and insulin action, but no studies have evaluated its use in pregnancy with pump therapy. Until such data emerge, established rapid-acting analogs remain the preferred choices for pump use in pregnancy.

Comprehensive Management Framework

Medical Nutrition Therapy

Dietary counseling forms the foundation of diabetes management in pregnancy. Consistent carbohydrate intake, spaced evenly across meals and snacks, helps match insulin dosing to glucose excursions. A diet emphasizing low-glycemic-index carbohydrates, lean protein sources, healthy fats, and fiber-rich foods can attenuate postprandial glucose spikes. Portion control and meal timing consistency become particularly important when using rapid-acting insulins with short duration of action, such as Lyumjev. Working with a registered dietitian experienced in diabetes and pregnancy can help patients develop individualized meal plans that align with their insulin regimen.

Physical Activity

Moderate physical activity, such as walking or swimming for 30 minutes on most days, improves insulin sensitivity and contributes to glycemic control in pregnancy. Post-meal exercise is particularly effective at reducing postprandial glucose excursions. However, exercise timing must be coordinated with insulin action to avoid exercise-induced hypoglycemia. Patients using Lyumjev should be counseled to monitor glucose before and after activity, particularly during the peak insulin action window.

Glycemic Targets in Pregnancy

Glycemic targets during pregnancy are more stringent than in non-pregnant adults. Standard targets include:

  • Fasting glucose: ≤95 mg/dL (5.3 mmol/L)
  • One-hour postprandial glucose: ≤140 mg/dL (7.8 mmol/L)
  • Two-hour postprandial glucose: ≤120 mg/dL (6.7 mmol/L)
  • Hemoglobin A1C: <6.0% (42 mmol/mol) if achievable without excessive hypoglycemia

These targets should be individualized based on the patient hypoglycemia history, glucose variability, and ability to monitor frequently. The tighter targets associated with pregnancy heighten the importance of selecting an insulin formulation whose action profile can be reliably matched to the patient eating patterns.

Glucose Monitoring and Technology

Self-monitoring of blood glucose is recommended at least four to six times daily during pregnancy: fasting, before each meal, one or two hours after the start of each meal, and at bedtime. Continuous glucose monitoring provides additional data on glycemic trends, nocturnal glucose patterns, and hypoglycemia detection. Evidence supports improved pregnancy outcomes with CGM use, particularly for women with type 1 diabetes. For patients using Lyumjev, CGM with predictive low-glucose alerts is strongly recommended to capture the rapid declines that can occur with this formulation.

Team-Based Care

Optimal management of diabetes in pregnancy requires a multidisciplinary approach. The care team should include an endocrinologist or diabetologist, a maternal-fetal medicine specialist, a certified diabetes care and education specialist, a registered dietitian, and obstetrical providers. Frequent visits — often every one to two weeks during the second and third trimesters — allow timely insulin dose adjustments as insulin resistance evolves. If Lyumjev is considered, the decision should be made collaboratively with the patient after thorough discussion of the available evidence and unknowns. Documentation of informed consent is advisable when using Lyumjev off-label in pregnancy.

Clinical Scenarios Where Lyumjev Might Be Considered

Given the absence of robust pregnancy-specific safety data, Lyumjev is not a first-line insulin option for pregnant women. However, specific clinical scenarios may warrant consideration after careful risk-benefit analysis:

  • Women who were well-controlled on Lyumjev prior to conception and express strong preference to continue the same formulation. In such cases, detailed counseling about the limited pregnancy data is essential.
  • Patients with persistent postprandial hyperglycemia despite optimized doses of insulin aspart or Humalog, particularly when CGM data suggest that delayed insulin absorption contributes to the problem.
  • Participation in a clinical trial or structured compassionate use program with mandated frequent monitoring and data collection.

In nearly all cases, switching to Humalog or insulin aspart is straightforward, cost-equivalent, and removes the uncertainty associated with Lyumjev unstudied formulation in pregnancy. The clinical benefit of Lyumjev over these established alternatives has not been demonstrated in pregnancy, and the potential advantages are theoretical rather than evidence-based.

Evidence-Based Recommendations for Clinicians

Key clinical takeaway: Lyumjev should not be used as a routine first-line rapid-acting insulin in pregnant women with diabetes. The available evidence does not support its safety advantage over established alternatives, and the absence of pregnancy-specific clinical trials represents a significant knowledge gap.

For pregnant women requiring insulin therapy, the following hierarchy of insulin selection is supported by current evidence and guidelines:

  1. First-line rapid-acting options: Insulin aspart (NovoLog) or insulin lispro (Humalog), both with extensive pregnancy safety data and guideline endorsement.
  2. Alternative rapid-acting option: Human regular insulin, particularly when cost or access limits analog availability, or when a longer duration of action is clinically desirable.
  3. Reserve option: Lyumjev, only in exceptional circumstances where established options have failed and after thorough informed consent and implementation of intensive monitoring protocols.

Clinicians should document their rationale for selecting Lyumjev, the counseling provided regarding unknown fetal risks, and the monitoring plan in place. This documentation supports both patient safety and medicolegal clarity.

Future Directions: Needed Research

The evidence gap surrounding Lyumjev in pregnancy underscores the need for dedicated investigation. Prospective observational studies enrolling pregnant women using Lyumjev — whether by choice or by clinical necessity — would provide pharmacokinetic data, glycemic outcomes, and preliminary safety signals. A pregnancy registry specifically designed to capture outcomes in women exposed to Lyumjev could generate useful comparative data. Ideally, a randomized controlled trial comparing Lyumjev to insulin aspart or Humalog in pregnancy would provide definitive evidence, though practical and ethical considerations make such a trial challenging to conduct. Until such data emerge, clinicians and patients must make decisions based on the best available evidence — which currently favors established insulin formulations with proven safety records.

Conclusion

Lyumjev represents a genuine pharmacologic advancement in rapid-acting insulin technology for non-pregnant adults with diabetes. For pregnant women, however, the formulation remains an unstudied option whose theoretical benefits are outweighed by the absence of safety data. The potential for tighter postprandial glucose control must be weighed against the concrete risks of hypoglycemia and the uncertainty regarding long-term fetal outcomes. Insulin aspart, insulin lispro (Humalog), and human regular insulin offer decades of accumulated clinical experience demonstrating both safety and efficacy in pregnancy. These established options should remain the standard of care. Clinicians who choose to use Lyumjev in pregnancy should do so only in exceptional cases, with meticulous monitoring, shared decision-making with the patient, and clear documentation. The principle of first, do no harm guides this conservative approach — one that prioritizes known safety over theoretical advantage.

For additional information, consult the FDA prescribing information for Lyumjev, the American Diabetes Association Standards of Medical Care in Diabetes, and the ACOG Practice Bulletin on Gestational Diabetes. These resources offer current guidance for evidence-based diabetes management during pregnancy.